182 related articles for article (PubMed ID: 32929567)
1. Racial and ethnic disparities in 21-gene recurrence scores, chemotherapy, and survival among women with hormone receptor-positive, node-negative breast cancer.
Han Y; Miao ZF; Lian M; Peterson LL; Colditz GA; Liu Y
Breast Cancer Res Treat; 2020 Dec; 184(3):915-925. PubMed ID: 32929567
[TBL] [Abstract][Full Text] [Related]
2. Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test results.
Press DJ; Ibraheem A; Dolan ME; Goss KH; Conzen S; Huo D
Breast Cancer Res Treat; 2018 Feb; 168(1):207-220. PubMed ID: 29181717
[TBL] [Abstract][Full Text] [Related]
3. Association of Race/Ethnicity and the 21-Gene Recurrence Score With Breast Cancer-Specific Mortality Among US Women.
Hoskins KF; Danciu OC; Ko NY; Calip GS
JAMA Oncol; 2021 Mar; 7(3):370-378. PubMed ID: 33475714
[TBL] [Abstract][Full Text] [Related]
4. Reduction in Breast Cancer Death With Adjuvant Chemotherapy Among US Women According to Race, Ethnicity, and the 21-Gene Recurrence Score.
Huang HC; Calip GS; Weiss J; Simons Y; Gadi VK; Danciu OC; Rauscher GH; Hoskins KF
J Natl Compr Canc Netw; 2024 Jan; 22(1D):e237077. PubMed ID: 38190799
[TBL] [Abstract][Full Text] [Related]
5. Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial.
Albain KS; Gray RJ; Makower DF; Faghih A; Hayes DF; Geyer CE; Dees EC; Goetz MP; Olson JA; Lively T; Badve SS; Saphner TJ; Wagner LI; Whelan TJ; Ellis MJ; Wood WC; Keane MM; Gomez HL; Reddy PS; Goggins TF; Mayer IA; Brufsky AM; Toppmeyer DL; Kaklamani VG; Berenberg JL; Abrams J; Sledge GW; Sparano JA
J Natl Cancer Inst; 2021 Apr; 113(4):390-399. PubMed ID: 32986828
[TBL] [Abstract][Full Text] [Related]
6. 21-Gene recurrence scores: racial differences in testing, scores, treatment, and outcome.
Lund MJ; Mosunjac M; Davis KM; Gabram-Mendola S; Rizzo M; Bumpers HL; Hearn S; Zelnak A; Styblo T; O'Regan RM
Cancer; 2012 Feb; 118(3):788-96. PubMed ID: 21720988
[TBL] [Abstract][Full Text] [Related]
7. Racial and Ethnic Disparities in Locoregional Recurrence Among Patients With Hormone Receptor-Positive, Node-Negative Breast Cancer: A Post Hoc Analysis of the TAILORx Randomized Clinical Trial.
Kantor O; King TA; Freedman RA; Mayer EL; Chavez-MacGregor M; Korde LA; Sparano JA; Mittendorf EA
JAMA Surg; 2023 Jun; 158(6):583-591. PubMed ID: 37043210
[TBL] [Abstract][Full Text] [Related]
8. Oncotype DX recurrence score implications for disparities in chemotherapy and breast cancer mortality in Georgia.
Collin LJ; Yan M; Jiang R; Ward KC; Crawford B; Torres MA; Gogineni K; Subhedar PD; Puvanesarajah S; Gaudet MM; McCullough LE
NPJ Breast Cancer; 2019; 5():32. PubMed ID: 31583272
[TBL] [Abstract][Full Text] [Related]
9. Socioecologic Factors and Racial Differences in Breast Cancer Multigene Prognostic Scores in US Women.
Parab AZ; Kong A; Lee TA; Kim K; Nutescu EA; Malecki KC; Hoskins KF; Calip GS
JAMA Netw Open; 2024 Apr; 7(4):e244862. PubMed ID: 38568689
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the Genomic Landscape Between Primary Breast Cancer in African American Versus White Women and the Association of Racial Differences With Tumor Recurrence.
Keenan T; Moy B; Mroz EA; Ross K; Niemierko A; Rocco JW; Isakoff S; Ellisen LW; Bardia A
J Clin Oncol; 2015 Nov; 33(31):3621-7. PubMed ID: 26371147
[TBL] [Abstract][Full Text] [Related]
11. Racial Differences in 21-Gene Recurrence Scores Among Patients With Hormone Receptor-Positive, Node-Negative Breast Cancer.
Holowatyj AN; Cote ML; Ruterbusch JJ; Ghanem K; Schwartz AG; Vigneau FD; Gorski DH; Purrington KS
J Clin Oncol; 2018 Mar; 36(7):652-658. PubMed ID: 29341832
[TBL] [Abstract][Full Text] [Related]
12. Variation in Breast Cancer Subtype Incidence and Distribution by Race/Ethnicity in the United States From 2010 to 2015.
Kong X; Liu Z; Cheng R; Sun L; Huang S; Fang Y; Wang J
JAMA Netw Open; 2020 Oct; 3(10):e2020303. PubMed ID: 33074325
[TBL] [Abstract][Full Text] [Related]
13. Risk of Recurrence and Mortality in a Multi-Ethnic Breast Cancer Population.
Kabat GC; Ginsberg M; Sparano JA; Rohan TE
J Racial Ethn Health Disparities; 2017 Dec; 4(6):1181-1188. PubMed ID: 28004356
[TBL] [Abstract][Full Text] [Related]
14. The 21-Gene Recurrence Score Assay for Node-Positive, Early-Stage Breast Cancer and Impact of RxPONDER Trial on Chemotherapy Decision-Making: Have Clinicians Already Decided?
Jasem J; Fisher CM; Amini A; Shagisultanova E; Rabinovitch R; Borges VF; Elias A; Kabos P
J Natl Compr Canc Netw; 2017 Apr; 15(4):494-503. PubMed ID: 28404760
[No Abstract] [Full Text] [Related]
15. Evaluation of Racial/Ethnic Differences in Treatment and Mortality Among Women With Triple-Negative Breast Cancer.
Cho B; Han Y; Lian M; Colditz GA; Weber JD; Ma C; Liu Y
JAMA Oncol; 2021 Jul; 7(7):1016-1023. PubMed ID: 33983438
[TBL] [Abstract][Full Text] [Related]
16. Racial/ethnic differences in 21-gene recurrence score and survival among patients with estrogen receptor-positive breast cancer.
Gill J; Yendamuri K; Chatterjee U; Yao S; Oladeru OT; Singh AK; Ma SJ
BMC Cancer; 2024 Apr; 24(1):461. PubMed ID: 38614979
[TBL] [Abstract][Full Text] [Related]
17. Differences in treatment and survival among African-American and Caucasian women with early stage operable breast cancer.
Sail K; Franzini L; Lairson D; Du X
Ethn Health; 2012; 17(3):309-23. PubMed ID: 22066691
[TBL] [Abstract][Full Text] [Related]
18. Do breast quadrants explain racial disparities in breast cancer outcomes?
Han Y; Moore JX; Langston M; Fuzzell L; Khan S; Lewis MW; Colditz GA; Liu Y
Cancer Causes Control; 2019 Nov; 30(11):1171-1182. PubMed ID: 31456108
[TBL] [Abstract][Full Text] [Related]
19. Trend and survival benefit of Oncotype DX use among female hormone receptor-positive breast cancer patients in 17 SEER registries, 2004-2015.
Zhang L; Hsieh MC; Petkov V; Yu Q; Chiu YW; Wu XC
Breast Cancer Res Treat; 2020 Apr; 180(2):491-501. PubMed ID: 32060781
[TBL] [Abstract][Full Text] [Related]
20. Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors.
Warner ET; Tamimi RM; Hughes ME; Ottesen RA; Wong YN; Edge SB; Theriault RL; Blayney DW; Niland JC; Winer EP; Weeks JC; Partridge AH
J Clin Oncol; 2015 Jul; 33(20):2254-61. PubMed ID: 25964252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
